Literature DB >> 16273601

Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.

Hong-Wei Shen1, Shun-Liang Gao, Yu-Lian Wu, Shu-You Peng.   

Abstract

AIM: To characterize the expression and genomic amplification of decoy receptor 3 (DcR3) in hepatocellular carcinoma (HCC) and to evaluate the role of DcR3 in apoptosis.
METHODS: We examined 48 cases of HCC for DcR3 expression by RT-PCR and DcR3 gene amplification by quantitative genomic PCR. DcR3 protein was detected by immunohistochemistry. Terminal deoxynucleotidyl transferase-mediated dUTP digoxigenin nick and labeling (TUNEL) was used to identify the apoptosis cells in tissues. Primary hepatoma cell culture and MTT test were used to evaluate the protection against FasL- and chemical-induced apoptosis by DcR3 expression.
RESULTS: DcR3 mRNA overexpression was detected in 60% HCC (29/48) patients. The occurrence of HCC was not associated with amplification of the gene. One sample base substitution was found in three sites as sequence in Genbank. The expression of DcR3 in HCC was the associatied with the apoptotic index (0.067+/-0.04 vs 0.209+/-0.12, P<0.01), size of mass, stage and infiltration or metastasis (41.2% vs 71.0%, 40% vs 75%, 51.8% vs 84.6%, P<0.05). DcR3 expression could be protect hepatoma cells against apoptosis induced by FasL, but not by chemicals.
CONCLUSION: These data suggest that in addition to gene amplification there may be another mechanism underlying DcR3 overexpression. The effect of overexpression of DcR3 on the apoptosis of cancer cells may have direct therapeutic implications for the management of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273601      PMCID: PMC4436712          DOI: 10.3748/wjg.v11.i38.5926

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.

Authors:  T Otsuki; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; H Ueki; M Kusaka; S Kita; A Ueki
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis.

Authors:  S Strand; W J Hofmann; A Grambihler; H Hug; M Volkmann; G Otto; H Wesch; S M Mariani; V Hack; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon.

Authors:  T Shinomiya; T Mori; Y Ariyama; T Sakabe; Y Fukuda; Y Murakami; Y Nakamura; J Inazawa
Journal:  Genes Chromosomes Cancer       Date:  1999-04       Impact factor: 5.006

4.  Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization.

Authors:  R A Altura; J M Maris; H Li; J M Boyett; G M Brodeur; A T Look
Journal:  Genes Chromosomes Cancer       Date:  1997-07       Impact factor: 5.006

5.  [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].

Authors:  Hong-wei Shen; Yu-lian Wu; Shu-you Peng
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2003-05-10

6.  Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions.

Authors:  M Muleris; A Almeida; M Gerbault-Seureau; B Malfoy; B Dutrillaux
Journal:  Genes Chromosomes Cancer       Date:  1995-11       Impact factor: 5.006

7.  DcR3/TR6 effectively prevents islet primary nonfunction after transplantation.

Authors:  Yulian Wu; Bing Han; Hongyu Luo; Raphael Roduit; Theodora W Salcedo; Paul A Moore; Jun Zhang; Jiangping Wu
Journal:  Diabetes       Date:  2003-09       Impact factor: 9.461

8.  Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.

Authors:  Yulian Wu; Bing Han; Hongwei Sheng; Min Lin; Paul A Moore; Jun Zhang; Jiangping Wu
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

9.  Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.

Authors:  Chia-Ron Yang; Shie-Liang Hsieh; Che-Ming Teng; Feng-Ming Ho; Wen-Ling Su; Wan-Wan Lin
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.

Authors:  Shoichiro Tsuji; Ryo Hosotani; Shin Yonehara; Toshihiko Masui; Sidhartha S Tulachan; Sanae Nakajima; Hiroyuki Kobayashi; Masayuki Koizumi; Eiji Toyoda; Daisuke Ito; Kazuhiro Kami; Tomohiko Mori; Koji Fujimoto; Ryuichiro Doi; Masayuki Imamura
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

View more
  16 in total

Review 1.  The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.

Authors:  Marcos W Steinberg; Timothy C Cheung; Carl F Ware
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

2.  Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.

Authors:  Jing Tong; Ran Ao; Ying Wang; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.

Authors:  Timothy C Cheung; Ken Coppieters; Hideki Sanjo; Lisa M Oborne; Paula S Norris; Amy Coddington; Steven W Granger; Dirk Elewaut; Carl F Ware
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

4.  Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Authors:  Zhicheng Ge; Andrew J Sanders; Lin Ye; Wen G Jiang
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

5.  Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.

Authors:  Cheng-Hsun Ho; Chen-Fang Hsu; Pei-Fen Fong; Shyh-Kuan Tai; Shie-Liang Hsieh; Chi-Ju Chen
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

6.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.

Authors:  C R Yang; J H Guh; C M Teng; C C Chen; P H Chen
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

8.  Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.

Authors:  Jintaek Im; Kyutae Kim; Polla Hergert; Richard Seonghun Nho
Journal:  J Pathol       Date:  2016-07-14       Impact factor: 7.996

9.  Significance of increased expression of decoy receptor 3 in chronic liver disease.

Authors:  S Kim; V Kotoula; P Hytiroglou; D Zardavas; L Zhang
Journal:  Dig Liver Dis       Date:  2009-02-04       Impact factor: 4.088

10.  DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.

Authors:  Joseph P Connor; Mildred Felder; Arvinder Kapur; Nonyem Onujiogu
Journal:  BMC Cancer       Date:  2012-05-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.